Eric Blount

Array ( [id] => 15147587 [patent_doc_number] => 20190352271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => MCL-1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/410457 [patent_app_country] => US [patent_app_date] => 2019-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 97371 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16410457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16230512 [patent_doc_number] => 10738050 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-11 [patent_title] => 4H-pyrido[1,2-A]pyrimidin-4-one compounds [patent_app_type] => utility [patent_app_number] => 16/409296 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29440 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 209 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14777865 [patent_doc_number] => 20190263830 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMORPHIC FORMS ALPHA, BETA, AND GAMMA OF RIFAXIMIN [patent_app_type] => utility [patent_app_number] => 16/409398 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5485 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14777863 [patent_doc_number] => 20190263829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN [patent_app_type] => utility [patent_app_number] => 16/409324 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4753 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16777987 [patent_doc_number] => 20210115064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/054118 [patent_app_country] => US [patent_app_date] => 2019-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11319 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17022256 [patent_doc_number] => 20210246127 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => COMPOUNDS AND METHODS TARGETING GPER FOR TREATMENT OF DISEASES ASSOCIATED WITH CALCIUM [patent_app_type] => utility [patent_app_number] => 17/052584 [patent_app_country] => US [patent_app_date] => 2019-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25650 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17307317 [patent_doc_number] => 11208409 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => Substituted xanthines and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/397697 [patent_app_country] => US [patent_app_date] => 2019-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61155 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16397697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15083597 [patent_doc_number] => 20190336609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors [patent_app_type] => utility [patent_app_number] => 16/398011 [patent_app_country] => US [patent_app_date] => 2019-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69530 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16398011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715405 [patent_doc_number] => 20190248766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => ADDITIVE FOR IMPARTING ULTRAVIOLET ABSORBENCY AND/OR HIGH REFRACTIVE INDEX TO MATRIX, AND RESIN MEMBER USING SAME [patent_app_type] => utility [patent_app_number] => 16/394302 [patent_app_country] => US [patent_app_date] => 2019-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16394302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16870031 [patent_doc_number] => 20210163498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => SOLID STATE FORMS OF LORLATINIB AND THEIR PREPARATION [patent_app_type] => utility [patent_app_number] => 17/047417 [patent_app_country] => US [patent_app_date] => 2019-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14914 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17047417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711876 [patent_doc_number] => 20210079023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF AS ANTITUMOUR AGENTS [patent_app_type] => utility [patent_app_number] => 17/046498 [patent_app_country] => US [patent_app_date] => 2019-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35118 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18013261 [patent_doc_number] => 11505543 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-22 [patent_title] => 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication [patent_app_type] => utility [patent_app_number] => 17/042413 [patent_app_country] => US [patent_app_date] => 2019-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47062 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 198 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042413 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15083607 [patent_doc_number] => 20190336614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => TARGETED PYRROLOBENZODIAZAPINE CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/381448 [patent_app_country] => US [patent_app_date] => 2019-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36517 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16381448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885347 [patent_doc_number] => 20210171542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => DI(HETERO)ARYL MACROCYCLIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/047877 [patent_app_country] => US [patent_app_date] => 2019-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17047877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17111719 [patent_doc_number] => 20210292316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => COMPOUNDS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/046245 [patent_app_country] => US [patent_app_date] => 2019-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -154 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19027272 [patent_doc_number] => 11926619 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-12 [patent_title] => Certain pladienolide compounds and methods of use [patent_app_type] => utility [patent_app_number] => 17/045952 [patent_app_country] => US [patent_app_date] => 2019-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 97337 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 295 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17045952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17815364 [patent_doc_number] => 11420962 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => Indene derivatives useful in treating pain and inflammation [patent_app_type] => utility [patent_app_number] => 17/045626 [patent_app_country] => US [patent_app_date] => 2019-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53317 [patent_no_of_claims] => 58 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 857 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17045626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15254057 [patent_doc_number] => 20190375762 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => MK2 INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/375317 [patent_app_country] => US [patent_app_date] => 2019-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57549 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16375317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18315083 [patent_doc_number] => 11629152 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-18 [patent_title] => Compound with anticancer activity [patent_app_type] => utility [patent_app_number] => 17/043348 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91311 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1389 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18315083 [patent_doc_number] => 11629152 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-18 [patent_title] => Compound with anticancer activity [patent_app_type] => utility [patent_app_number] => 17/043348 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91311 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1389 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043348 [rel_patent_id] =>[rel_patent_doc_number] =>)